Almagate
{{Short description|Chemical compound}}
{{Drugbox
| verifiedrevid = 443400546
| IUPAC_name =
| image =
| tradename =
| Drugs.com = {{drugs.com|international|almagate}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration = Oral
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 66827-12-1
| ATC_prefix = A02
| ATC_suffix = AD03
| PubChem = 71749
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64792
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 568Z59H7ZJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02821
| chemical_formula = Al2Mg6(OH)14(CO3)2 · 4 H2O
| molecular_weight = 314.99
| molecular_weight_comment = g/mol
| smiles = [Al+3].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[O-]C([O-])=O.[OH-].[OH-].[OH-].[OH-].O.O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/CH2O3.Al.3Mg.9H2O/c2-1(3)4;;;;;;;;;;;;;/h(H2,2,3,4);;;;;9*1H2/q;+3;3*+2;;;;;;;;;/p-9
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MTEOMEWVDVPTNN-UHFFFAOYSA-E
}}
Almagate (trade name Almax) is an aluminium- and magnesium-containing antacid. It was first described in 1984.{{cite journal | vauthors = Moragues J, Beneyto JE, Fábregas JL, Spickett RG | title = Characterization of a new crystalline synthetic gastric antacid, almagate | journal = Arzneimittel-Forschung | volume = 34 | issue = 10A | pages = 1346–9 | year = 1984 | pmid = 6548918 | url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2 | format = Free full text }}{{cite journal | vauthors = Beneyto JE, Fábregas JL, Moragues J, Spickett RG | title = Evaluation of a new antacid, almagate | journal = Arzneimittel-Forschung | volume = 34 | issue = 10A | pages = 1350–4 | year = 1984 | pmid = 6439224 | url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2 | format = Free full text }}
Adverse effects
Almagate is well tolerated. In a clinical trial, the most common adverse effects were diarrhea and nausea.{{cite journal | vauthors = Suau A, Dominguez Martin A, Ferrando Cucarella J, Juncosa Iglesias L, Muñoz Benitez J, Nieto Calvet M, Pérez Gieb J, Pérez Mota A, Pineda Garcia A, Rodriguez Sanchez E | display-authors = 6 | title = Treatment of gastric pyrosis with almagate in patients with and without endoscopically demonstrable duodenal ulcer. A multicentre clinical trial | journal = Arzneimittel-Forschung | volume = 34 | issue = 10A | pages = 1380–3 | year = 1984 | pmid = 6548926 | url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2 | format = Free full text }}
References
{{Reflist}}
{{Antacids}}
{{gastrointestinal-drug-stub}}